The Experts below are selected from a list of 1107 Experts worldwide ranked by ideXlab platform
Marianna Bugiani - One of the best experts on this subject based on the ideXlab platform.
-
multiregional Tumor drug uptake imaging by pet and microvascular morphology in end stage diffuse intrinsic Pontine glioma
The Journal of Nuclear Medicine, 2018Co-Authors: Sophie Veldhuijzen E M Van Zanten, Charlotte A P Sewing, Arthur Van Lingen, Otto S Hoekstra, Pieter Wesseling, Michael H Meel, Dannis G Van Vuurden, Gertjan J L Kaspers, Esther Hulleman, Marianna BugianiAbstract:Inadequate Tumor uptake of the vascular endothelial growth factor antibody bevacizumab could explain lack of effect in diffuse intrinsic Pontine glioma. Methods: By combining data from a PET imaging study using 89Zr-labeled bevacizumab and an autopsy study, a 1-on-1 analysis of multiregional in vivo and ex vivo 89Zr-bevacizumab uptake, Tumor histology, and vascular morphology in a diffuse intrinsic Pontine glioma patient was performed. Results: In vivo 89Zr-bevacizumab measurements showed heterogeneity between lesions. Additional ex vivo measurements and immunohistochemistry of cervicomedullary metastasis samples showed uptake to be highest in the area with marked microvascular proliferation. In the primary Pontine Tumor, all samples showed similar vascular morphology. Other histologic features were similar between the samples studied. Conclusion: In vivo 89Zr-bevacizumab PET serves to identify heterogeneous uptake between Tumor lesions, whereas subcentimeter intralesional heterogeneity could be identified only by ex vivo measurements. 89Zr-bevacizumab uptake is enhanced by vascular proliferation, although our results suggest it is not the only determinant of intralesional uptake heterogeneity.
Sophie Veldhuijzen E M Van Zanten - One of the best experts on this subject based on the ideXlab platform.
-
multiregional Tumor drug uptake imaging by pet and microvascular morphology in end stage diffuse intrinsic Pontine glioma
The Journal of Nuclear Medicine, 2018Co-Authors: Sophie Veldhuijzen E M Van Zanten, Charlotte A P Sewing, Arthur Van Lingen, Otto S Hoekstra, Pieter Wesseling, Michael H Meel, Dannis G Van Vuurden, Gertjan J L Kaspers, Esther Hulleman, Marianna BugianiAbstract:Inadequate Tumor uptake of the vascular endothelial growth factor antibody bevacizumab could explain lack of effect in diffuse intrinsic Pontine glioma. Methods: By combining data from a PET imaging study using 89Zr-labeled bevacizumab and an autopsy study, a 1-on-1 analysis of multiregional in vivo and ex vivo 89Zr-bevacizumab uptake, Tumor histology, and vascular morphology in a diffuse intrinsic Pontine glioma patient was performed. Results: In vivo 89Zr-bevacizumab measurements showed heterogeneity between lesions. Additional ex vivo measurements and immunohistochemistry of cervicomedullary metastasis samples showed uptake to be highest in the area with marked microvascular proliferation. In the primary Pontine Tumor, all samples showed similar vascular morphology. Other histologic features were similar between the samples studied. Conclusion: In vivo 89Zr-bevacizumab PET serves to identify heterogeneous uptake between Tumor lesions, whereas subcentimeter intralesional heterogeneity could be identified only by ex vivo measurements. 89Zr-bevacizumab uptake is enhanced by vascular proliferation, although our results suggest it is not the only determinant of intralesional uptake heterogeneity.
Charlotte A P Sewing - One of the best experts on this subject based on the ideXlab platform.
-
multiregional Tumor drug uptake imaging by pet and microvascular morphology in end stage diffuse intrinsic Pontine glioma
The Journal of Nuclear Medicine, 2018Co-Authors: Sophie Veldhuijzen E M Van Zanten, Charlotte A P Sewing, Arthur Van Lingen, Otto S Hoekstra, Pieter Wesseling, Michael H Meel, Dannis G Van Vuurden, Gertjan J L Kaspers, Esther Hulleman, Marianna BugianiAbstract:Inadequate Tumor uptake of the vascular endothelial growth factor antibody bevacizumab could explain lack of effect in diffuse intrinsic Pontine glioma. Methods: By combining data from a PET imaging study using 89Zr-labeled bevacizumab and an autopsy study, a 1-on-1 analysis of multiregional in vivo and ex vivo 89Zr-bevacizumab uptake, Tumor histology, and vascular morphology in a diffuse intrinsic Pontine glioma patient was performed. Results: In vivo 89Zr-bevacizumab measurements showed heterogeneity between lesions. Additional ex vivo measurements and immunohistochemistry of cervicomedullary metastasis samples showed uptake to be highest in the area with marked microvascular proliferation. In the primary Pontine Tumor, all samples showed similar vascular morphology. Other histologic features were similar between the samples studied. Conclusion: In vivo 89Zr-bevacizumab PET serves to identify heterogeneous uptake between Tumor lesions, whereas subcentimeter intralesional heterogeneity could be identified only by ex vivo measurements. 89Zr-bevacizumab uptake is enhanced by vascular proliferation, although our results suggest it is not the only determinant of intralesional uptake heterogeneity.
Dannis G Van Vuurden - One of the best experts on this subject based on the ideXlab platform.
-
multiregional Tumor drug uptake imaging by pet and microvascular morphology in end stage diffuse intrinsic Pontine glioma
The Journal of Nuclear Medicine, 2018Co-Authors: Sophie Veldhuijzen E M Van Zanten, Charlotte A P Sewing, Arthur Van Lingen, Otto S Hoekstra, Pieter Wesseling, Michael H Meel, Dannis G Van Vuurden, Gertjan J L Kaspers, Esther Hulleman, Marianna BugianiAbstract:Inadequate Tumor uptake of the vascular endothelial growth factor antibody bevacizumab could explain lack of effect in diffuse intrinsic Pontine glioma. Methods: By combining data from a PET imaging study using 89Zr-labeled bevacizumab and an autopsy study, a 1-on-1 analysis of multiregional in vivo and ex vivo 89Zr-bevacizumab uptake, Tumor histology, and vascular morphology in a diffuse intrinsic Pontine glioma patient was performed. Results: In vivo 89Zr-bevacizumab measurements showed heterogeneity between lesions. Additional ex vivo measurements and immunohistochemistry of cervicomedullary metastasis samples showed uptake to be highest in the area with marked microvascular proliferation. In the primary Pontine Tumor, all samples showed similar vascular morphology. Other histologic features were similar between the samples studied. Conclusion: In vivo 89Zr-bevacizumab PET serves to identify heterogeneous uptake between Tumor lesions, whereas subcentimeter intralesional heterogeneity could be identified only by ex vivo measurements. 89Zr-bevacizumab uptake is enhanced by vascular proliferation, although our results suggest it is not the only determinant of intralesional uptake heterogeneity.
Esther Hulleman - One of the best experts on this subject based on the ideXlab platform.
-
multiregional Tumor drug uptake imaging by pet and microvascular morphology in end stage diffuse intrinsic Pontine glioma
The Journal of Nuclear Medicine, 2018Co-Authors: Sophie Veldhuijzen E M Van Zanten, Charlotte A P Sewing, Arthur Van Lingen, Otto S Hoekstra, Pieter Wesseling, Michael H Meel, Dannis G Van Vuurden, Gertjan J L Kaspers, Esther Hulleman, Marianna BugianiAbstract:Inadequate Tumor uptake of the vascular endothelial growth factor antibody bevacizumab could explain lack of effect in diffuse intrinsic Pontine glioma. Methods: By combining data from a PET imaging study using 89Zr-labeled bevacizumab and an autopsy study, a 1-on-1 analysis of multiregional in vivo and ex vivo 89Zr-bevacizumab uptake, Tumor histology, and vascular morphology in a diffuse intrinsic Pontine glioma patient was performed. Results: In vivo 89Zr-bevacizumab measurements showed heterogeneity between lesions. Additional ex vivo measurements and immunohistochemistry of cervicomedullary metastasis samples showed uptake to be highest in the area with marked microvascular proliferation. In the primary Pontine Tumor, all samples showed similar vascular morphology. Other histologic features were similar between the samples studied. Conclusion: In vivo 89Zr-bevacizumab PET serves to identify heterogeneous uptake between Tumor lesions, whereas subcentimeter intralesional heterogeneity could be identified only by ex vivo measurements. 89Zr-bevacizumab uptake is enhanced by vascular proliferation, although our results suggest it is not the only determinant of intralesional uptake heterogeneity.